A better understanding of how leukemias develop, combined with the creation of targeted therapies, has improved the prognosis for patients with AML. However, rapid diagnostics are essential for personalized therapy. In this work, we have shown that deep learning can assist in identifying AML patients with an IDH1 mutation.
Read the full article here: https://www.nature.com/articles/s41698-026-01762-x
